Mursla Bio
- Company typePrivate
- Founded2019
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Mursla Bio firmographics
Firmographics- Name
- Mursla Bio
- Legal name
- Mursla Ltd. / Mursla Inc.
- Website
- https://mursla.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Mursla Bio industry classification
Industry- Product category
- Liquid Biopsy Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)
Keywords
Where Mursla Bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Mursla Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Developed Tests (LDT): Mursla Bio is advancing towards launching EvoLiver as a laboratory developed test (LDT), generating revenue through diagnostic testing services offered via their own or partner CLIA-certified laboratories.
- Pharmaceutical Partnerships and Collaborations: Revenue generated through partnerships with pharmaceutical companies for drug development, patient stratification, and companion diagnostics development using the AI Precision Medicine Platform. The company collaborates with unnamed global pharma for MASH drug development and biomarker-guided precision medicine.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Mursla Bio product offering
Product offeringCore offering
Mursla Bio develops and commercializes an AI Precision Medicine Platform that isolates organ-specific extracellular vesicles (EVs) from blood to generate multi-omics data for precision diagnostics and biomarker discovery. Its flagship clinical product, EvoLiver, is a blood test for liver cancer surveillance in high-risk cirrhotic patients, supported by a CLIA-certified laboratory testing channel and pharmaceutical partnership services for biomarker-guided drug development.
Product overview
Mursla Bio offers an AI Precision Medicine Platform that enables organ-specific molecular insights from blood samples through extracellular vesicle (EV) isolation and multiomics analysis. The platform underpins the company's flagship product EvoLiver™, a blood test for liver cancer surveillance in high-risk patients with cirrhosis. The company is extending its platform to cardiometabolic, lung, and neurological indications.
Differentiator
Problem solved
Functional benefit
Brands
- EvoLiver: A blood test for liver cancer surveillance in high-risk populations with cirrhosis, built on Mursla Bio's AI Precision Medicine Platform. Received FDA Breakthrough Device Designation in April 2025.
- AI Precision Medicine Platform
- NEXOS
- ExoPheno
Products and services
- AI Precision Medicine Platform A proprietary platform that isolates organ-specific extracellular vesicles (EVs) from blood samples to generate biologically labeled, multi-omics data (proteomics and RNA sequencing) with the resolution of tissue biopsy without invasiveness. It enables AI-powered biomarker discovery and IVD translation for precision medicine applications, including pharmaceutical collaborations for patient stratification and companion diagnostics in metabolic liver diseases such as MASH.
- EvoLiver A flagship blood test for liver cancer surveillance designed to detect hepatocellular carcinoma early in high-risk populations with cirrhosis. Built on the AI Precision Medicine Platform, it achieved 86% sensitivity and 88% specificity for early-stage HCC detection in the MEV01 study and is being advanced as a Laboratory Developed Test (LDT) in preparation for US commercial launch via a CLIA-certified laboratory.
Quantifiable outcome
- 86% early-stage sensitivity and 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients
- +2 more outcomes
Companies that use Mursla Bio
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Mursla Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Mursla Bio partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and supporting.
- Association of British HealthTech Industries (ABHI)coreMursla Bio selected to join ABHI US Accelerator program to support introduction of EvoLiver to US market. Program provides structured access to over 300 senior healthcare leaders across 35 leading hospitals, 20 health systems, and US insurers, along with operational guidance from Becton Dickinson, Dell Medical School at the University of Texas, and ABHI's US advisor network.
- Becton DickinsonsupportingBecton Dickinson provides operational guidance as part of ABHI US Accelerator program to support Mursla Bio's commercial deployment of EvoLiver in the US market.
- Dell Medical School at the University of TexassupportingDell Medical School at the University of Texas provides operational guidance as part of ABHI US Accelerator program to support Mursla Bio's US market entry strategy.
- Leading global pharmaceutical company (unnamed)coreCollaboration to apply AI Precision Medicine Platform toward biomarker-guided drug development and patient stratification in metabolic dysfunction-associated steatohepatitis (MASH). Mursla Bio generates hepatocyte-specific EV profiles from patient blood samples to explore mode-of-action biomarkers and identify patients likely to benefit from the pharma company's investigational therapy. Initial phase builds high-dimensional mRNA and protein datasets for MASH pathways and patient stratification signatures.
- Evotec International GmbHsupportingEvotec contributed key supporting proteomics data for validation of hepatocyte EV isolation method published as pre-print. Collaboration demonstrated platform's capability for liver diseases.
- University College LondoncoreUCL provided patient samples and Professor Brian Davidson (global leader in liver disease surgery and clinical research) contributed as co-author on hepatocyte EV isolation validation pre-print. UCL is a key collaboration partner in MEV01 multi-center clinical study for EvoLiver validation.
- EVEREST ConsortiumsupportingMursla Bio selected to join EVEREST, a leading European consortium advancing EV research, innovation and clinical translation. Consortium comprises 22 institutions and 80+ Marie Curie Scientific fellows across 11 European countries. Mursla Bio provides oversight on scaling and commercialization work package for EV products and clinical diagnostics, and hosts researchers from institutions across Europe.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Mursla Bio competitors and assessment
Company assessmentDirect peers
- Owlstone Medical: UK-based diagnostics company developing breath-based and EV-based biomarker tests for early disease detection, including in liver disease. Directly comparable as a UK-headquartered EV/biomarker diagnostics peer targeting similar clinical indications and payor pathways.
- Bio-Techne (ExosomeDx): Bio-Techne's ExosomeDx division commercializes ExoFlo, an FDA-authorized extracellular vesicle-based liquid biopsy test for prostate cancer. Most directly comparable peer as another EV-based IVD developer with approved clinical tests in a multi-cancer liquid biopsy workflow.
Broad incumbents
- GRAIL: Developer of Galleri, a blood-based multi-cancer early detection test using methylation-based cfDNA technology. Comparable as a large-scale, well-funded blood-based cancer detection commercial-stage peer with overlapping clinical surveillance and screening use cases.
- Exact Sciences (Thrive Earlier Detection): Commercial-stage diagnostics company with Cologuard and the acquired Thrive Earlier Detection multi-cancer screening program. Competes in adjacent blood-based cancer detection and shares a similar commercial/regulatory playbook for payor adoption.
- Guardant Health: Leading commercial liquid biopsy company offering cfDNA-based oncology tests (Guardant360, Reveal) and MRD/screening applications. Comparable as a competing blood-based cancer detection platform pursuing similar physician and payor relationships in oncology.
Regional players
- Genfit: French biotech developing diagnostics and therapeutics for MASH and liver diseases, including NIS4 blood-based molecular diagnostic for MASH. Comparable as a peer operating in liver/MASH biomarker diagnostics with overlapping patient stratification and pharma partnership use cases.
Emerging players
- Codiak BioSciences: Pioneer in engineered exosome/EV therapeutics and diagnostics platform with deep expertise in EV isolation and characterization. Comparable as a peer operating in the EV technology stack with overlapping scientific and IP considerations.
- Personalis: Genomics-based oncology diagnostics company offering ImmunoID Next and other tumor-informed liquid biopsy assays. Comparable as a peer combining AI/multiomics analysis with blood-based cancer detection in a commercial/regulatory stage similar to Mursla Bio's trajectory.
- Adela: Cell-free DNA methylation-based multi-cancer detection developer with a focus on minimal residual disease and early detection. Comparable as an emerging blood-based cancer detection competitor pursuing the same clinical and commercial audiences as Mursla Bio.
- Freenome: Multiomics blood-based early cancer detection company combining cfDNA, methylation, and protein signals for colorectal and other cancers. Comparable as a venture-stage multiomics blood diagnostics peer pursuing similar evidence and reimbursement trajectories.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mursla Bio social profiles
Digital presenceMursla Bio compliance and trust
Trust signalCompliance1 record
Mursla Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mursla Bio leadership team
Management profileNumber of profiles
Profiles14 records
Mursla Bio funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mursla Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mursla Bio
What does Mursla Bio do?
Mursla Bio develops and commercializes an AI Precision Medicine Platform that isolates organ-specific extracellular vesicles (EVs) from blood to generate multi-omics data for precision diagnostics and biomarker discovery. Its flagship clinical product, EvoLiver, is a blood test for liver cancer surveillance in high-risk cirrhotic patients, supported by a CLIA-certified laboratory testing channel and pharmaceutical partnership services for biomarker-guided drug development.
Is Mursla Bio a public or private company?
Mursla Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mursla Bio founded?
Mursla Bio was founded in 2019. It employs 11 to 50 people.
Where is Mursla Bio based?
Mursla Bio is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Mursla Bio make money?
Two revenue lines are on record. Laboratory Developed Tests (LDT) is the primary driver. The others are pharmaceutical Partnerships and Collaborations.
Who are Mursla Bio's main competitors?
Direct peers on record are Owlstone Medical and Bio-Techne (ExosomeDx). Broad incumbents are GRAIL, Exact Sciences (Thrive Earlier Detection) and Guardant Health. Genfit is listed as a regional player. Emerging players are Codiak BioSciences, Personalis, Adela and Freenome.
Does Mursla Bio have an API?
No public API is recorded for Mursla Bio.
What industry is Mursla Bio in?
Mursla Bio's product category is Liquid Biopsy Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 621511 and its SIC code is 2835.